Clinical trials: Large B Cell Diffuse Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03277729
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B Cell Lymphoma
Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab
The RTXM83-AC-01-11 study evaluated efficacy and safety outcomes in relation to the use of Vivaxxia during 6 treatment cycles (at the investigator's discretion, up to 8 treatment cycles could be administered), followed by 9…
- Trial name
- NCT04928573
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Libbs Farmacêutica LTDA
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
- Trial name
- NCT05131022
- Testing
- NX-5948
- Where
- 62 sites in United States, France and 6 more
- Volunteers
- 572 people
- Sponsor
- Nurix Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma (DLBCL)
DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma
Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% of all DLBCL with overall cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as R-CHOP14.
- Trial name
- NCT01066429
- Testing
- Dexamethasone and dose-dense immunochemoterapy
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Principe de Asturias
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in…
- Trial name
- NCT03843294
- Testing
- TAA-T cells, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Catherine Bollard
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
DLBCL, MCL
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
This is a prospective, single arm,single centre open-label, phase II study in relapsed or refractory DLBCL and MCL non-Hodgkin's lymphoma (NHL), not suitable to other therapies, included HDCT, or patients relapsed after high-dose…
- Conditions
- DLBCL, MCL, Recurrent Disease
- Trial name
- itTRIOlym (NCT02488512)
- Testing
- 90Y-DOTATOC
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Chronic Lymphocytic Leukemia
AMG 319 Lymphoid Malignancy FIH
This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies
- Trial name
- NCT01300026
- Testing
- AMG 319
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amgen
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers.
- Conditions
- Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
- Trial name
- NCT07226843
- Testing
- LY4584180, Rituximab
- Where
- 46 sites in United States, France and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Lymphoma, B-Cell
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06693830
- Testing
- Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua-Jay J Cherng, MD
HIV Infections, Diffuse Large B Cell Lymphoma
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Main objective: To evaluate the applicability of the treatment: 1. To evaluate the treatment toxicity according to the Common Terminology Criteria (CTC) version 3.0 of the National Cancer Institute (NCI). 2.
- Trial name
- LINFOTARGAM (NCT00466258)
- Testing
- R-CHOP, Highly active antiretroviral therapy, Central nervous system (CNS) prophylaxis
- Where
- 15 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients
This is a prospective , open, multicenter, randomized phase Ⅲ study. The investigators planed to include 732 untreated CD20 positive diffused large B cell lymphoma adults,to random to R-CHOP21, CHOP14 , R-CHOP14 regimen groups…
- Trial name
- NCT01793844
- Where
- China
- Volunteers
- 732 people
- Sponsor
- Sun Yat-sen University
Leukemia, Lymphoma
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
The goal of this clinical research study is to learn if researchers can successfully and safely give HSCT patients an infusion of white blood cells (called T-cells) that have been genetically changed.
- Trial name
- NCT01497184
- Testing
- HSCT, DLI
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.